207 related articles for article (PubMed ID: 11290431)
1. The significance of dihydropyrimidine dehydrogenase (DPD) activity in bladder cancer.
Mizutani Y; Wada H; Fukushima M; Yoshida O; Ukimura O; Kawauchi A; Miki T
Eur J Cancer; 2001 Mar; 37(5):569-75. PubMed ID: 11290431
[TBL] [Abstract][Full Text] [Related]
2. Significance of dihydropyrimidine dehydrogenase activity in renal cell carcinoma.
Mizutani Y; Wada H; Yoshida O; Fukushima M; Nakanishi H; Nakao M; Miki T
Eur J Cancer; 2003 Mar; 39(4):541-7. PubMed ID: 12751387
[TBL] [Abstract][Full Text] [Related]
3. Clinical significance of thymidine phosphorylase and dihydropyrimidine dehydrogenase expression in transitional cell cancer.
Hirano Y; Kageyama S; Ushiyama T; Suzuki K; Fujita K
Cancer Chemother Pharmacol; 2003 Jan; 51(1):29-35. PubMed ID: 12497203
[TBL] [Abstract][Full Text] [Related]
4. Significance of thymidylate synthase activity in renal cell carcinoma.
Mizutani Y; Wada H; Yoshida O; Fukushima M; Nonomura M; Nakao M; Miki T
Clin Cancer Res; 2003 Apr; 9(4):1453-60. PubMed ID: 12684419
[TBL] [Abstract][Full Text] [Related]
5. Thymidine phosphorylase and dihydropyrimidine dehydrogenase in bladder cancer.
Iizumi T; Hariu K; Sato M; Sato S; Shimizu H; Tomomasa H; Umeda T
Urol Int; 2002; 68(2):122-5. PubMed ID: 11834904
[TBL] [Abstract][Full Text] [Related]
6. Prognostic significance of a combination of thymidylate synthase and dihydropyrimidine dehydrogenase activities in grades 1 and 2 superficial bladder cancer.
Mizutani Y; Wada H; Yoshida O; Fukushima M; Bonavida B; Kawauchi A; Miki T
Oncol Rep; 2002; 9(2):289-92. PubMed ID: 11836594
[TBL] [Abstract][Full Text] [Related]
7. Thymidine phosphorylase and dihydropyrimidine dehydrogenase in renal cell carcinoma: relationship between histological parameters and chemosensitivity to 5-fluorouracil.
Hirano Y; Takayama T; Kageyama S; Ushiyama T; Suzuki K; Fujita K
Eur Urol; 2003 Jan; 43(1):45-51; discussion 51-2. PubMed ID: 12507543
[TBL] [Abstract][Full Text] [Related]
8. Clinical implications of dihydropyrimidine dehydrogenase (DPD) activity in 5-FU-based chemotherapy: mutations in the DPD gene, and DPD inhibitory fluoropyrimidines.
Omura K
Int J Clin Oncol; 2003 Jun; 8(3):132-8. PubMed ID: 12851836
[TBL] [Abstract][Full Text] [Related]
9. Prognostic significance of thymidylate synthase activity in bladder carcinoma.
Mizutani Y; Wada H; Ogawa O; Yoshida O; Fukushima M; Nonomura N; Miki T
Cancer; 2001 Aug; 92(3):510-8. PubMed ID: 11505394
[TBL] [Abstract][Full Text] [Related]
10. Dihydropyrimidine dehydrogenase and messenger RNA levels in gastric cancer: possible predictor for sensitivity to 5-fluorouracil.
Ishikawa Y; Kubota T; Otani Y; Watanabe M; Teramoto T; Kumai K; Takechi T; Okabe H; Fukushima M; Kitajima M
Jpn J Cancer Res; 2000 Jan; 91(1):105-12. PubMed ID: 10744051
[TBL] [Abstract][Full Text] [Related]
11. Prognostic significance of orotate phosphoribosyltransferase activity in bladder carcinoma.
Mizutani Y; Wada H; Fukushima M; Yoshida O; Nakanishi H; Li YN; Miki T
Cancer; 2004 Feb; 100(4):723-31. PubMed ID: 14770427
[TBL] [Abstract][Full Text] [Related]
12. Thymidine phosphorylase and dihydropyrimidine dehydrogenase activity in colorectal carcinoma and patients prognosis.
Ikeguchi M; Makino M; Kaibara N
Langenbecks Arch Surg; 2002 Oct; 387(5-6):240-5. PubMed ID: 12410361
[TBL] [Abstract][Full Text] [Related]
13. Significance of 5-fluorouracil-related enzyme activities in predicting sensitivity to 5-fluorouracil in bladder carcinoma.
Furuse H; Hirano Y; Harada M; Ming LH; Aoki T; Kurita Y; Mugiya S; Ushiyama T; Ozono S
Anticancer Res; 2009 Apr; 29(4):1001-8. PubMed ID: 19414338
[TBL] [Abstract][Full Text] [Related]
14. The significance of the expression of dihydropyrimidine dehydrogenase in prostate cancer.
Li Y; Mizutani Y; Shiraishi T; Nakamura T; Mikami K; Takaha N; Okihara K; Kawauchi A; Sakai T; Miki T
BJU Int; 2007 Mar; 99(3):663-8. PubMed ID: 17092280
[TBL] [Abstract][Full Text] [Related]
15. 5-fluorouracil and dihydropyrimidine dehydrogenase.
Kubota T
Int J Clin Oncol; 2003 Jun; 8(3):127-31. PubMed ID: 12851835
[TBL] [Abstract][Full Text] [Related]
16. Dihydropyrimidine dehydrogenase: a tumoral target for fluorouracil modulation.
Fischel JL; Etienne MC; Spector T; Formento P; Renée N; Milano G
Clin Cancer Res; 1995 Sep; 1(9):991-6. PubMed ID: 9816071
[TBL] [Abstract][Full Text] [Related]
17. Enhancement of the antitumour activity of 5-fluorouracil (5-FU) by inhibiting dihydropyrimidine dehydrogenase activity (DPD) using 5-chloro-2,4-dihydroxypyridine (CDHP) in human tumour cells.
Takechi T; Fujioka A; Matsushima E; Fukushima M
Eur J Cancer; 2002 Jun; 38(9):1271-7. PubMed ID: 12044515
[TBL] [Abstract][Full Text] [Related]
18. Role of dihydropyrimidine dehydrogenase inhibitory fluoropyrimidine against non-small cell lung cancer--in correlation with the tumoral expression of thymidylate synthase and dihydropyrimidine dehydrogenase.
Inoue K; Takao M; Watanabe F; Tarukawa T; Shimamoto A; Kaneda M; Sakai T; Fukushima M; Shimpo H; Yada I
Lung Cancer; 2005 Jul; 49(1):47-54. PubMed ID: 15949589
[TBL] [Abstract][Full Text] [Related]
19. Synergistic antitumor effect of combined 5-fluorouracil (5-FU) with 5-chloro-2,4-dihydroxypyridine on 5-FU-resistant gastric cancer cells: possible role of a dihydropyrimidine dehydrogenase-independent mechanism.
Sasaki E; Tominaga K; Kuwamura H; Watanabe T; Fujiwara Y; Oshitani N; Higuchi K; Arakawa T
J Gastroenterol; 2007 Oct; 42(10):816-22. PubMed ID: 17940834
[TBL] [Abstract][Full Text] [Related]
20. 5-fluorouracil sensitivity and dihydropyrimidine dehydrogenase activity in advanced gastric cancer.
Inada T; Ogata Y; Kubota T; Tomikawa M; Yamamoto S; Andoh J; Ozawa I; Hishinuma S; Shimizu H; Kotake K
Anticancer Res; 2000; 20(4):2457-62. PubMed ID: 10953310
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
